| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | STMN1 |
| Uniprot No | P16949 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-149aa |
| 氨基酸序列 | ASSDIQVKELEKRASGQAFELILSPRSKESVPEFPLSPPKKKDLSLEEIQ KKLEAAEERRKSHEAEVLKQLAEKREHEKEVLQKAIEENNNFSKMAEEKL THKMEANKENREAQMAAKLERLREKDKHIEEVRKNKESKDPADETEAD |
| 预测分子量 | 18 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于STMN1重组蛋白的3篇文献示例(注：文献信息为模拟概括，仅供参考)：
---
1. **标题**：*"Recombinant human STMN1 promotes microtubule depolymerization and enhances chemosensitivity in cancer cells"*
**作者**：Chen, Y., et al.
**摘要**：研究通过原核系统表达并纯化重组人STMN1蛋白，证实其通过促进微管解聚抑制肿瘤细胞增殖，并增强紫杉醇等化疗药物的敏感性。
2. **标题**：*"Functional analysis of STMN1 phosphorylation mutants using recombinant protein expression"*
**作者**：Belletti, B., et al.
**摘要**：构建STMN1磷酸化突变体重组蛋白，发现特定位点磷酸化调控其与微管蛋白的结合能力，进而影响细胞周期进程。
3. **标题**：*"STMN1 recombinant protein delivery suppresses metastasis in preclinical models of breast cancer"*
**作者**：Wang, X., et al.
**摘要**：利用重组STMN1蛋白处理乳腺癌细胞，发现其通过抑制微管动态性降低细胞迁移和侵袭能力，提示潜在抗转移治疗价值。
---
**说明**：以上文献为模拟示例，实际文献需通过PubMed、Google Scholar等平台检索关键词(如STMN1 recombinant protein、stathmin-1 expression)获取。
STMN1 (Stathmin-1), also known as oncoprotein 18 (OP18), is a cytosolic phosphoprotein encoded by the STMN1 gene. It plays a critical role in regulating microtubule dynamics by binding to tubulin heterodimers or promoting microtubule depolymerization, thereby influencing cell cycle progression, mitosis, and intracellular transport. Its activity is tightly controlled by phosphorylation; hyperphosphorylation inactivates its microtubule-destabilizing function. Overexpression of STMN1 is linked to enhanced cell proliferation, metastasis, and poor prognosis in various cancers, including breast, lung, and liver cancers. It has also been implicated in neurodevelopmental processes and neurodegenerative disorders.
Recombinant STMN1 protein is engineered for in vitro studies to elucidate its molecular mechanisms and therapeutic potential. Produced using expression systems like E. coli or mammalian cells, the recombinant protein retains functional domains necessary for tubulin interaction. It is typically purified via affinity tags (e.g., His-tag) and validated for bioactivity, such as microtubule polymerization inhibition assays. Researchers utilize this protein to investigate STMN1's role in cancer signaling pathways, drug resistance mechanisms, and its interplay with kinases (e.g., CDK1. MAPK). Additionally, it serves as an antigen for antibody development in diagnostic assays. Recent studies explore STMN1 as a biomarker for early cancer detection or a target for small-molecule inhibitors to restore microtubule stability in malignant cells. Its recombinant form enables high-throughput screening of therapeutic compounds and structure-function analyses to guide precision oncology strategies.
×
